# SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)

> **NCT00002960** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 59 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Metastatic Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **BIOLOGICAL:** recombinant adenovirus-p53 SCH-58500

## Key facts

- **NCT ID:** NCT00002960
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-06
- **Primary completion:** 2000-07
- **Final completion:** 2000-07
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2016-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002960, "SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00002960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*